Medical devices incorporating collagen inhibitors

Abstract

Provided herein are implantable or insertable biomedical devices comprising a substrate and a collagen inhibitor on or in said substrate, and methods of treatment using the same. In some embodiments, the device is a urethral, ureteral, or nephroureteral catheter or stent. In some embodiments, the device is an absorbable esophageal or tracheal stent. Wound closure devices are also provided herein, including a substrate and a collagen inhibitor on or in the substrate. Also provided are surgical packings, including a substrate and a collagen inhibitor on or in the substrate. A barrier material for preventing adhesions in a subject is further provided, including a preformed or in situ formable barrier substrate and a collagen inhibitor on or in the substrate. Kits comprising the coated substrates are also provided.

1 .- 8 . (canceled) 
     
     
         9 . A surgical packing comprising a substrate and a collagen inhibitor on or in said substrate. 
     
     
         10 . The packing of  claim 9 , wherein said substrate comprises a material selected from the group consisting of: oxycellulose, methylcellulose, hydroxypropylmethylcellulose, hydroxybutylmethylcellulose, hydroxyethylmethylcellulose, ethylhydroxyethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, carboxymethylcellulose, microcrystalline cellulose, xanthan gum, silicon dioxide, and mixtures thereof. 
     
     
         11 . The packing of  claim 10 , wherein said substrate is in the form of a dry powder. 
     
     
         12 . The packing of  claim 10 , wherein said packing is a sinus packing. 
     
     
         13 . The packing of  claim 10 , wherein said collagen inhibitor is selected from the group consisting of: mithramycin, mitomycin-c, tranilast, halofuginone and analogs thereof. 
     
     
         14 . A method of treating a paranasal sinus wound in a subject in need thereof comprising topically administering a collagen inhibitor in an amount effective to treat said wound. 
     
     
         15 . The method of  claim 14 , wherein said administering step is carried out by packing said paranasal sinus with a sinus packing material comprising said collagen inhibitor. 
     
     
         16 . The method of  claim 15 , wherein said sinus packing material comprises a cellulose compound. 
     
     
         17 . The method of  claim 15 , wherein said sinus packing material comprises a sinus packing gel. 
     
     
         18 . The method of  claim 14 , wherein said collagen inhibitor is selected from the group consisting of: mithramycin, mitomycin-c, tranilast, halofuginone and analogs thereof. 
     
     
         19 . An implantable or insertable biomedical device comprising a substrate and a collagen inhibitor on or in said substrate, said collagen inhibitor selected from the group consisting of: mithramycin, mitomycin-c, tranilast, halofuginone and analogs thereof. 
     
     
         20 . The device of  claim 19 , wherein said substrate is comprised of a material selected from the group consisting of vinyl, polyethylene, poly(vinyl chloride) (PVC), ethylene vinyl acetate (EVA), silicone, latex, and polypropylene. 
     
     
         21 . A method of treating a esophageal or tracheal stricture in a subject in need thereof comprising topically administering a collagen inhibitor in an amount effective to treat said stricture in said subject. 
     
     
         22 . The method of  claim 21 , wherein said administering step is carried out by stenting said stricture with a biodegradable stent comprising said collage inhibitor. 
     
     
         23 . The method of  claim 21 , wherein said collagen inhibitor is selected from the group consisting of: mithramycin, mitomycin-c, tranilast, halofuginone and analogs thereof. 
     
     
         24 . A barrier material for preventing adhesions in a subject, comprising a preformed or in situ formable barrier substrate and a collagen inhibitor on or in said substrate. 
     
     
         25 . The barrier material of  claim 24 , wherein said collagen inhibitor is selected from the group consisting of: mithramycin, mitomycin-c, tranilast, halofuginone and analogs thereof. 
     
     
         26 . A method of treating abdominal adhesions in a subject in need thereof comprising topically administering into the abdominal cavity of said subject a collagen inhibitor in an amount effective to treat said abdominal adhesions in said subject. 
     
     
         27 . The method of  claim 26 , wherein said collagen inhibitor is selected from the group consisting of: mithramycin, mitomycin-c, tranilast, halofuginone and analogs thereof. 
     
     
         28 - 33 . (canceled)